(Q58903536)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Long-term effects of amino-bisphosphonates on circulating γδ T cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Luca Idolazzi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

davide gatti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Silvano Adami

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ombretta Viapiana

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Elena Fracassi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Riccardo Ortolani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Antonio Vella

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Roberta Zanotti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Gaia Tripi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

4 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

Calcified Tissue International

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

395-399

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00223-012-9647-9

10 March 2020

exact match

0 references

cites work

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Characterization of and risk factors for the acute-phase response after zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Perspectives of gammadelta T cells in tumor immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Use of bisphosphonates and reduced risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-012-9647-9

10.1007/S00223-012-9647-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23052225%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference